COX-2 Woes’ Impact On Wholesaler Revenues Are Minimal, ABC Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
AmerisourceBergen would lose about 1% of revenues if all COX-2 inhibitors were withdrawn from the market, CEO David Yost said Jan. 25